source
- Roche signs $1.53 billion licensing deal with Simcere for preclinical B-cell antibodyRoche announced a licensing agreement with China's Simcere Zaiming, paying $75 million upfront and potentially up to $1.53 billion in total, for worldwide rights to a preclinical trispecific antibo…
- GSK's mRNA flu vaccine shows stronger immune response than standard shots in phase 2, prompting phase 3 launchGSK reported that its experimental mRNA seasonal influenza vaccine generated higher immune responses than both standard and high-dose flu shots in a phase-2 study involving nearly 1,000 adults. Th…